Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 1948-1960

  Parekh, Vrajesh V ^a   Wu, Lan ^a   Olivares Villagómez, Danyvid ^a   Wilson, Keith T ^a,b   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ARGINASE 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPLETION; ENZYME SYNTHESIS; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNITY; CELL COMMUNICATION; CELL MOVEMENT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GALACTOSYLCERAMIDES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, TRANSGENIC; MYELOID CELLS; NATURAL KILLER T-CELLS; NITRIC OXIDE SYNTHASE TYPE II; SPLEEN; TRANSPLANTATION CHIMERA; WHOLE-BODY IRRADIATION;

EID: 84874226238     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201718     Document Type: Article

References (63)

1. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
2. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513.
3. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900.
4. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
5. Parekh, V. V., S. Lalani, and L. Van Kaer. 2007. The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol. 26: 31-48.
6. Matsuda, J. L., T. Mallevaey, J. Scott-Browne, and L. Gapin. 2008. CD1drestricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr. Opin. Immunol. 20: 358-368.
7. Van Kaer, L., V. V. Parekh, and L. Wu. 2011. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 3: 59-75.
8. Van Kaer, L., V. V. Parekh, and L. Wu. 2011. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res. 343: 43-55.
9. Van Kaer, L. 2005. a-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5: 31-42.
10. Wilson, S. B., and T. L. Delovitch. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3: 211-222.
11. Parekh, V. V., M. T. Wilson, D. Olivares-Villagómez, A. K. Singh, L. Wu, C. R. Wang, S. Joyce, and L. Van Kaer. 2005. Glycolipid antigen induces longterm natural killer T cell anergy in mice. J. Clin. Invest. 115: 2572-2583.
12. Van Kaer, L, and V V Parekh, and W. L. 2012. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol. DOI: 10.1016/j. it.2012.08.009.
13. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagómez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
14. Parekh, V. V., A. K. Singh, M. T. Wilson, D. Olivares-Villagómez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, et al. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J. Immunol. 173: 3693-3706.
15. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
16. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799.
17. Pál, E., T. Tabira, T. Kawano, M. Taniguchi, S. Miyake, and T. Yamamura. 2001. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J. Immunol. 166: 662-668.
18. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by alpha- GalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33: 1830-1838.
19. Mars, L. T., L. Araujo, P. Kerschen, S. Diem, E. Bourgeois, L. P. Van, N. Carrié, M. Dy, R. S. Liblau, and A. Herbelin. 2009. Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl. Acad. Sci. USA 106: 6238-6243.
20. Bunt, S. K., V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg. 2009. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85: 996-1004.
21. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
22. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
23. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by Larginine metabolism. Nat. Rev. Immunol. 5: 641-654.
24. Chioda, M., E. Peranzoni, G. Desantis, F. Papalini, E. Falisi, S. Solito, S. Mandruzzato, and V. Bronte. 2011. Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev. 30: 27-43.
25. Bronte, V. 2009. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 39: 2670-2672.
26. Rodriguez, P. C., M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, and A. C. Ochoa. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69: 1553-1560.
27. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477.
28. Stromnes, I. M., and J. M. Goverman. 2006. Passive induction of experimental allergic encephalomyelitis. Nat. Protoc. 1: 1952-1960.
29. Marigo, I., E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. Bicciato, E. Falisi, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32: 790-802.
30. Suzuki, E., V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda. 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721.
31. Ko, H. J., Y. J. Kim, Y. S. Kim, W. S. Chang, S. Y. Ko, S. Y. Chang, S. Sakaguchi, and C. Y. Kang. 2007. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67: 7477-7486.
32. Zhu, B., Y. Bando, S. Xiao, K. Yang, A. C. Anderson, V. K. Kuchroo, and S. J. Khoury. 2007. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179: 5228-5237.
33. Domingues, H. S., M. Mues, H. Lassmann, H. Wekerle, and G. Krishnamoorthy. 2010. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 5: e15531.
34. Damsker, J. M., A. M. Hansen, and R. R. Caspi. 2010. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 1183: 211-221.
35. Jadidi-Niaragh, F., and A. Mirshafiey. 2011. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 74: 1-13.
36. Segal, B. M. 2010. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 32: 71-77.
37. Fletcher, J. M., S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. H. Mills. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162: 1-11.
38. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
39. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
40. Bruchard, M., G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux, F. Vegran, W. Boireau, B. Simon, B. Ryffel, J. L. Connat, J. Kanellopoulos, F. Martin, C. Rebe, L. Apetoh, and F. Ghiringhelli. 2012. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. DOI: 10.1038/nm.2999.
41. Ioannou, M., T. Alissafi, I. Lazaridis, G. Deraos, J. Matsoukas, A. Gravanis, V. Mastorodemos, A. Plaitakis, A. Sharpe, D. Boumpas, and P. Verginis. 2012. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J. Immunol. 188: 1136-1146.
42. Zhu, B., J. K. Kennedy, Y. Wang, C. Sandoval-Garcia, L. Cao, S. Xiao, C. Wu, W. Elyaman, and S. J. Khoury. 2011. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J. Immunol. 187: 2418-2432.
43. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
44. Guerrero, A. R., K. Uchida, H. Nakajima, S. Watanabe, M. Nakamura, W. E. Johnson, and H. Baba. 2012. Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J. Neuroinflammation 9: 40-55.
45. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
46. Biermann, H., B. Pietz, R. Dreier, K. W. Schmid, C. Sorg, and C. Sunderkötter. 1999. Murine leukocytes with ring-shaped nuclei include granulocytes, monocytes, and their precursors. J. Leukoc. Biol. 65: 217-231.
47. Griewank, K., C. Borowski, S. Rietdijk, N. Wang, A. Julien, D. G. Wei, A. A. Mamchak, C. Terhorst, and A. Bendelac. 2007. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 27: 751-762.
48. Kojo, S., K. Seino, M. Harada, H. Watarai, H. Wakao, T. Uchida, T. Nakayama, and M. Taniguchi. 2005. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J. Immunol. 175: 3648-3655.
49. Denney, L., W. L. Kok, S. L. Cole, S. Sanderson, A. J. McMichael, and L. P. Ho. 2012. Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J. Immunol. 189: 551-557.
50. Cripps, J. G., and J. D. Gorham. 2011. MDSC in autoimmunity. Int. Immunopharmacol. 11: 789-793.
51. King, I. L., T. L. Dickendesher, and B. M. Segal. 2009. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113: 3190-3197.
52. Kotsianidis, I., J. D. Silk, E. Spanoudakis, S. Patterson, A. Almeida, R. R. Schmidt, C. Tsatalas, G. Bourikas, V. Cerundolo, I. A. Roberts, and A. Karadimitris. 2006. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood 107: 3138-3144.
53. Broxmeyer, H. E., K. Christopherson, G. Hangoc, S. Cooper, C. Mantel, G. J. Renukaradhya, and R. R. Brutkiewicz. 2012. CD1d expression on and regulation of murine hematopoietic stem and progenitor cells. Blood 119: 5731-5741.
54. Leite-de-Moraes, M. C., M. Lisbonne, A. Arnould, F. Machavoine, A. Herbelin, M. Dy, and E. Schneider. 2002. Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: relevance to peripheral myeloid recruitment. Eur. J. Immunol. 32: 1897-1904.
55. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777-2790.
56. De Santo, C., M. Salio, S. H. Masri, L. Y. Lee, T. Dong, A. O. Speak, S. Porubsky, S. Booth, N. Veerapen, G. S. Besra, et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloidderived suppressor cells in mice and humans. J. Clin. Invest. 118: 4036-4048.
57. Ko, H. J., J. M. Lee, Y. J. Kim, Y. S. Kim, K. A. Lee, and C. Y. Kang. 2009. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cellbased antitumor vaccine. J. Immunol. 182: 1818-1828.
58. Kmieciak, M., D. Basu, K. K. Payne, A. Toor, A. Yacoub, X. Y. Wang, L. Smith, H. D. Bear, and M. H. Manjili. 2011. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J. Immunol. 187: 708-717.
59. McIntosh, K. R., and D. B. Drachman. 1999. Induction of apoptosis in activated T cell blasts by suppressive macrophages: a possible immunotherapeutic approach for treatment of autoimmune disease. Cell. Immunol. 193: 24-35.
60. Kerr, E. C., B. J. Raveney, D. A. Copland, A. D. Dick, and L. B. Nicholson. 2008. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 31: 354-361.
61. Oh, K., O. J. Byoun, D. I. Ham, Y. S. Kim, and D. S. Lee. 2011. Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation. Eur. J. Immunol. 41: 392-402.
62. Liu, R., A. La Cava, X. F. Bai, Y. Jee, M. Price, D. I. Campagnolo, P. Christadoss, T. L. Vollmer, L. Van Kaer, and F. D. Shi. 2005. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175: 7898-7904.
63. Chiba, A., S. Oki, K. Miyamoto, H. Hashimoto, T. Yamamura, and S. Miyake. 2004. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 50: 305-313.